CN103877177B - Centipede pseudo-ginseng extract product preparation gout medicine in application and medicine - Google Patents
Centipede pseudo-ginseng extract product preparation gout medicine in application and medicine Download PDFInfo
- Publication number
- CN103877177B CN103877177B CN201410084518.8A CN201410084518A CN103877177B CN 103877177 B CN103877177 B CN 103877177B CN 201410084518 A CN201410084518 A CN 201410084518A CN 103877177 B CN103877177 B CN 103877177B
- Authority
- CN
- China
- Prior art keywords
- ginseng extract
- extract product
- pseudo
- centipede
- centipede pseudo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This application discloses centipede pseudo-ginseng extract product application in preparation treatment gout medicine and pharmaceutical composition thereof.Described centipede pseudo-ginseng extract product comprises Scolopendra Radix Notoginseng total arasaponins.Prepared by described centipede pseudo-ginseng extract product decocting method.Confirm that it has preferably treatment gout effect through pharmacological testing and clinical trial, possess the advantage of high-efficiency low-toxicity.Centipede pseudo-ginseng extract product has reduction serum uric acid level effect to hyperuricemia rat, and plays therapeutic effect not by expressing of suppression xanthine oxidase.Centipede pseudo-ginseng extract product has reduction serum uric acid level effect to hyperuricemia mice.
Description
Technical field
The present invention relates to medical usage and the pharmaceutical composition thereof of centipede pseudo-ginseng extract product.
Background technology
Gout (Gout) has become the metabolic disease of serious threat human health, and research in recent years finds antihyperuricemic
Disease (Hyperuricemia) is not only the most important biochemical basis of gout, the most closely related with metabolism disorder syndrome,
Being the independent risk factors such as cardiovascular disease, hypertension, kidney disease, the United Nations is classified as the 20 of 21 century
One of big pertinacious disease.Along with the continuous rising of gout sickness rate, the morbidity machine to hyperuricemia and gout in world wide
System increasingly receives publicity with controlling way.
High hematuria acid disease is the biochemical marker that gout is main, and gout is one group of different substantiality disease, and it is because of long-term fast
Purine dysbolismus and the blood uric acid (UA) that causes increase and the tissue-damaging heredity that causes or acquired metabolic
Disease.It is generally acknowledged on clinical medicine when the blood uric acid amount that body is for oral administration is higher than 416ttmol/L just for antihyperuricemic
Disease, patient with gout is necessarily accompanied by high hematuria acid disease, and find according to the study high hematuria acid disease and diabetes, obesity,
The disease such as hypertension, hyperlipemia is proportionate.And the Patients with Hyperuricemia of the most about 5%～12% can be
Develop into gout eventually.In recent years, the sickness rate of high hematuria acid disease and gout contains height day by day, and, have become as existing
One of principal disease, bring huge pressure to society, become the important directions of present scientific research.
Hyperuricemia can be divided into constitutional and secondary hyperuricemia two class, thus gout quilt by the reason formed
Being divided into primary gout and secondary gout, this is at present the most widely used a kind of simple and practical preliminary
Sorting technique.People lacks uricase (uricolysis can be made to become allantoin) with apes, is owing to evolving by inference
The natural selection caused through gene mutation in journey, loses the functional gene of coding uricase, and uric acid is that purine is at machine
The end-product of internal metabolism.Purine anabolism strengthens and/or underexcretion is that patient with gout serum uric acid increases
Original mechanism, the concentration of uric acid in blood depends on the balance between the generation of uric acid and excretion.In human body, uric acid has two
Individual source, vivo acid, ribose phosphate and the synthesis of other micromolecular compounds or nucleic acid decomposition metabolism produce (endogenous
Property), account for the 80% of internal total uric acid；(exogenous) is decomposed from the food center former times acid rich in purine or nucleoprotein,
Account for the 20% of internal total uric acid.Although the protopathy of high purine diet not gout because of, but absorb in a large number purine and can make
Extracellular fluid uric acid level changes rapidly, and this may often be such that the inducement of gouty arthritis acute attack.
The generation of uric acid includes main path and salvage pathway two parts.Main path i.e. body utilizes the precursor of non-purine
The approach of material synthesis uric acid.Specifically, i.e. first by ribose 5-phosphate at phosphoribosylpyrophosphate synthetase (PRPP
Synzyme) effect under generate phosphoribosylpyrophosphate (PRPP), then be combined with paddy ammonia phthalein amine, by paddy ammonia phthalein amine
The effect of transferring enzyme and adenine phosphoribosyl transferase (APRT) generates 1-amino-ribose 5-phosphate, the most successively
In conjunction with glycine, aspartic acid etc., through at least 9 steps, generate inosine monophosphate, IMP (IMP).IMP
Being a kind of important purine nucleotides, it can continue to generate guanylic acid (GMP) and gland under the effect of enzyme
Purine nucleotides (AMP).The effect finally relying on xanthine oxidase (XOD) generates uric acid.When body is urinated
After the main path of acid metabolic is obstructed, salvage pathway just plays Main Function, i.e. relies on hypoxanthine-guanine monophosphate core
Sugar transferring enzyme (HGPRT) and the effect of adenine phosphoribosyl transferase, by hypoxanthine, guanine, adenine
Generate IMP, GMP, AMP respectively, continue to the normal uric acid metabolism of body.XOD regulation and control uricopoiesis
Final link, therefore occupies an important position in the morbidity of hyperuricemia.Studies have found that, either lipid metabolism
Exception, or the exception of uric acid metabolism all can be with the horizontal abnormality of XOD, and this points out us, owing to XOD joins
With the nucleic acid metabolism of human body, and may act on multiple substrate, such as purine, pyrimidine, pteridine, heterocyclic bases, aldehydes, fat
Fat acid and phospholipid, therefore, it can the change from XOD start with inquire into internal uric acid level change reason.
Clinical treatment gout and the Western medicine of high hematuria acid disease at present, has and reaches fall by suppression xanthine oxidase activity
The allopurinol etc. of the effect of low blood uric acid, also has the probenecid etc. promoting blood uric acid metabolism.But, above medicine is normal
The untoward reaction such as anaphylaxis, hepatitis infringement occurs.And patient with gout is in addition to being accompanied by high hematuria acid disease, it is accompanied by
The inflammation of joint, congestion and swelling pain, also there is ancient book to say: " pain such as tiger is nibbled ", " gout pain has often place, and its sore spot is strengthened from head to foot
Hot or red swollen scorching hot ".Therefore patient with gout is also required to analgesia while long-term taking has reduction blood uric acid medicine, but
Be the most effective, economic, safe reduction UA and analgesic medicine less.China is using Chinese herbal medicine treatment gout
Sick aspect has long ground history, but the Chinese medicine preparation that can effectively reduce blood uric acid the most clinically is poor.
So, the medicine of novel fall blood uric acid is found in research, particularly drops the preparation of the Chinese herbal medicine of blood uric acid, has deep
Remote meaning.Have now been found that part Chinese herbal medicine not only has the effect of good easing pain and diminishing inflammation, it is also possible to preferably
Reduce blood uric acid and reach the effect for the treatment of.
Scolopendra Radix Notoginseng (Anemone fiaccida Fr. Schmidt), also known as woods shade Anemone cathayensis Kitag., is Ranunculaceae Anemone
How perennial plant, be used as medicine with rhizome, and its pharmacological action has anti-inflammatory and antalgic, antipyretic wind-damp dispelling etc. to act on, and it is effective
Composition is triterpene saponin.Therefore, this research is extracted from Scolopendra rhizomes of Panax notoginseng and isolates total saponins, carry out pharmacology
Experiment, observes the centipede pseudo-ginseng extract product impact on rat hyperuricemia, probes into its therapeutic potential and possible effect
Mechanism.
Summary of the invention
The purpose of the present invention aims to provide the centipede pseudo-ginseng extract product new opplication at medical field.
One aspect of the present invention provides centipede pseudo-ginseng extract product and at preparation prevention or Prevention or treats gout medicine
In application.
Another aspect of the present invention provides a kind of prevention or the pharmaceutical composition for the treatment of gout, comprises Scolopendra Radix Notoginseng and carries
Take thing or prepared by centipede pseudo-ginseng extract product.
Described centipede pseudo-ginseng extract product comprises Scolopendra Radix Notoginseng total arasaponins.
Preferably, prepared by described centipede pseudo-ginseng extract product decocting method, and decocting method can extract and be enough to prevent or treat gout
Composition.
Preferably, the extracting method of described centipede pseudo-ginseng extract product includes: add 2～the soak by water Herba Kyllingae three of 8 times of quality
Seven medical materials 3～5 times, each 1～4h；Then filter, concentrated filtrate, let cool；Adding ethanol makes containing alcohol capacity be 40～80%,
Stand after stirring evenly；Then filter, reclaim ethanol, evaporate into without alcohol taste, obtain extractum；Be dissolved in water described extractum, clear
Clearly；Upper nonpolar or low pole macroporous adsorptive resins, washes with water, then with 50～80% ethanol elution, collection is washed
De-liquid, reclaims ethanol, concentrates, dry, pulverize, sieves and get final product under vacuum.
The dosage form of the pharmaceutical composition of described prevention or treatment gout can be oral formulations.
Centipede pseudo-ginseng extract product of the present invention does not has reduction serum uric acid level effect to hyperuricemia rat, and not
It is to play therapeutic effect by expressing of suppression xanthine oxidase.Additionally, centipede pseudo-ginseng extract product of the present invention
Significantly decrease hyperuricemia mice serum uric acid level, and to the serum uric acid level of normal mouse without significance shadow
Ring.
Detailed description of the invention
Inventor have unexpectedly discovered that centipede pseudo-ginseng extract product application effect in prevention or treatment gout.
In order to be better understood from the essence of the present invention, the present invention illustrates that by the way of embodiment medicine of the present invention is to gout
The pharmacological testing of inhibitory action and clinical test results.Embodiments of the invention are for illustrating rather than
Limitation of the present invention.
One, the centipede pseudo-ginseng extract product impact on rat hyperuricemia
Gout, at many reasons such as the raising recently as dietetic level, the reductions of environmental quality, is increasingly becoming one
A kind of metabolic disease of common harm health of people.High hematuria acid disease is the important biochemical marker of gout morbidity,
So preventing and treating gout must control high hematuria acid disease, it is critically important for setting up high hematuria acid animal model in an experiment.This
Experiment use rat carry out the model of high hematuria acid disease, although the mammal in addition to the mankind, including rat
Internal all there is urate oxidase (urateoxidase) interior, uric acid is further broken into allantoin in vivo, tool
There is water solublity, generation crystallization will not be accumulated in vivo, do not result in high hematuria acid disease, so modeling is not easy to, can
Be rat be the laboratory animal that pharmacological evaluation is the most frequently used at ordinary times, be readily available, it is simple to raise, stable variety, thus use
Rat sets up the model of high hematuria acid disease by biochemical method, the most at home and abroad remains fairly common, so
Rat is used to carry out experimentation in this experiment.
1 experiment material
1.1 animal
Healthy Wistar rat, male, body weight 150～180g, dynamic by Lukang Medical Co., Ltd., Shandong's experiment
Thing room provides, the quality certification number: SCXK (Shandong) 2008-0002.In whole experimentation, except modeling in experiment
Outside particular/special requirement, animal is in freely drinking water and the state of diet, raises room temperature 22 ± 1 DEG C, raises humidity 55 ± 5 DEG C.
1.2 medicines and reagent
Centipede pseudo-ginseng extract product (total saponin content about 60%): prepared by conventional decocting method, take Scolopendra pseudo-ginseng, add 2～
The soak by water 3 of 8 times of quality～5 times, each 1～4h, filter, merging filtrate, filtrate is condensed into 60 DEG C the closeest
Degree 1.04～～the liquid of 1.1, let cool, add ethanol and make containing alcohol capacity be 40～80%, stir evenly, stand 12h, filter,
Reclaim ethanol, evaporate into without alcohol taste, obtain extractum, be dissolved in water, clarification, upper nonpolar or low pole macroporous absorption tree
Fat post, washes with water, discards, then with 50～80% ethanol elution, collects eluent, reclaim ethanol, concentrate, in
It is dried 12h under vacuum, pulverizes, cross 60 mesh sieves, obtain centipede pseudo-ginseng extract product.Described centipede pseudo-ginseng extract product is palm fibre
Yellow powder, is made into desired concn with distilled water.
Sodium carboxymethyl cellulose (CMC-Na): analytical pure, is provided by Chinese Medicine Solution on Chemical Reagents in Shanghai station.
Allopurinol (Allopurinol): lot number 11M1681V, is provided by Sigma-Aldrich company, with 0.5%
CMC-Na is made into desired concn.
Oxonic acid potassium salt (Oxonic acid potassium salt, purity 97%): lot number: STBC1486V, by
Sigma-Aldrich company provides, and is made into debita spissitudo with 0.5%CMC-Na.
Uric acid reagent box (urinary acidification): purchased from Shanghai Foxing Changzheng medical science Co., Ltd.
Xanthine oxidase test kit (xanthine oxidase, XOD): build up Bioengineering Research Institute purchased from Nanjing.
Coomassie brilliant blue protein quantification testing cassete: build up Bioengineering Research Institute purchased from Nanjing.
1.3 experimental apparatus
CJ-2F Medical purification workbench: Suzhou City Feng Laboratory Animal Equipment Co., Ltd；
AU400 automatic clinical chemistry analyzer: Japanese Olympus company；
DY89-1 type electric homogenate machine: the biotech inc that Ningbo is new；
KDC-160HR type High speed refrigerated centrifuge: Keda Innovation Co., Ltd；
Analytical balance, thermostat water bath, spectrophotometer.
2 experimental techniques
The impact on hyperuricemia rat uric acid of 2.1 centipede pseudo-ginseng extract product
2.1.1 packet and administration
Male rat 41, by body weight random packet: normal group, model group, centipede pseudo-ginseng extract product are high, medium and low
Dosage group (respectively 288mg/kg, 144mg/kg and 72mg/kg), positive controls (allopurinol 10mg/kg),
Totally 6 groups, often group 6-7 is only.Gastric infusion, every day 1 time, continuous 14 days.It is administered volume and presses 20mL/kg, be administered
Before all weigh rat body weight once, normal group and model group all give equal-volume distilled water.
After gastric infusion 10 days, each group rat starts lumbar injection oxonic acid potassium salt 200mg/kg every day, normal group abdomen
Isopyknic 0.5%CMC-Na is injected in chamber.After last is administered 1h, in addition to normal group, each group rats by intraperitoneal injection oxygen
Piperazine acid potassium salt 200mg/kg.After injection, 2h respectively organizes and all plucks eyeball and take blood (before taking blood, water is can't help in 12h fasting), under room temperature
Stand 1h, be centrifuged 10min at 3000r/min, take serum and be placed in 4 DEG C of preservations.Take the rat after blood and take off cervical vertebra execution,
Winning part of heart with eye scissors, weigh, in the normal saline of ice-water bath, rinsing removes blood, and filter paper is wiped dry, puts
In-20 DEG C of preservations.
2.1.2 test index
2.1.2.1 serum uric acid: take serum 200ul, is operated by uric acid reagent box description, uses Olympus AU400
Automatic clinical chemistry analyzer measures serum uric acid level.
2.1.2.2 liver xanthine oxidase (XOD): take liver, weighs, and in being inverted glass homogenizer, adds
The ice bath normal saline of precise volumes (15 times), grinds homogenate, at low-temperature and high-speed with electric homogenate machine in ice-water bath
In centrifuge, 4000r/min is centrifuged 15min, then takes supernatant, operates by protein quantification test kit description, light splitting light
At degree meter 595nm, meter calculates liver protein concentration, computing formula:
Operating by XOD test kit description, under spectrophotometer 530nm, measure and calculation goes out XOD vigor, calculates
Formula:
2.1.3 statistical procedures
Result is with mean ± standard deviationRepresent, between two groups, compare t inspection, P < 0.05, represent difference tool
Statistically significant.
3. experimental result
The impact on hyperuricemia rat blood serum uric acid level of 3.1 centipede pseudo-ginseng extract product
The results are shown in Table 1.Compared with normal group, model group rats serum uric acid level significantly increases, diversity notable (**P
< 0.01), high crow hematic acid disease modeling success is described.Compare with model group group, each treatment group (centipede pseudo-ginseng extract product
High, medium and low dosage group；Allopurinol group) all can reduce the uric acid level of metabolic arthritis rat to some extent, present
Significant difference (*P < 0.05,**P < 0.01), the effect of Qi Zhonggao, middle dosage group fall hematic acid is preferable, but with the most fast
Purine alcohol group compares, and the uric acid resisting action intensity of centipede pseudo-ginseng extract product is relatively weaker than allopurinol group.
Table 1 centipede pseudo-ginseng extract product impact on hyperuricemia rat serum uric acid
| Group | Dosage (mg/kg) | Number of animals | Serum uric acid level (mmol/L) |
| Normal group | - | 6 | 31.20±3.02** |
| Model group | - | 6 | 206.63±25.31 |
| Centipede pseudo-ginseng extract product high dose group | 288 | 6 | 1 64.08±20.39** |
| Dosage group in centipede pseudo-ginseng extract product | 144 | 7 | 1 58.77±32.07** |
| Centipede pseudo-ginseng extract product low dose group | 72 | 7 | 172.94±16.42* |
| Allopurinol group | 10 | 7 | 141.54±23.42** |
Note: compare with model group,*P < 0.05,**P<0.01。
The impact on high hematuria acid disease rat liver homogenate XOD vigor of 3.2 centipede pseudo-ginseng extract product
The results are shown in Table 2.Comparing with normal group, the XOD vigor of model group rats is higher, and modeling success is described.With mould
Type group compares, flaccid anemone total saponins each dosage group to high hematuria acid disease rat liver XOD activity level without notable shadow
Ring；Allopurinol group is inhibited to high hematuria acid disease rat liver XOD activity level, and it is the poorest to have
Different (P < 0.01).
The impact on hyperuricemia rat liver X0D vigor of table 2 centipede pseudo-ginseng extract product
| Group | Dosage (mg/kg) | Number of animals | XOD vigor (U/g) |
| Normal group | - | 6 | 38.69±2.58* |
| Model group | - | 6 | 43.78±4.72 |
| Centipede pseudo-ginseng extract product high dose group | 288 | 6 | 44.91±8.23 |
| Dosage group in centipede pseudo-ginseng extract product | 144 | 7 | 41.44±2.65 |
| Centipede pseudo-ginseng extract product low dose group | 72 | 7 | 47.17±6.72 |
| Allopurinol group | 10 | 7 | 35.76±3.28** |
Note: compare with model group, * P < 0.05,**P<0.01。
4 discuss
Seeing in the experiment that the centipede pseudo-ginseng extract product serum uric acid value for hyperuricemia rat model affects, from number
According to it can be seen that dosage group high, middle can significantly decrease uric acid level, and significant difference, there is statistical significance (P
<0.01)；Low dose group also can significantly reduce uric acid level, and difference also has statistical significance (P < 0.05).
In centipede pseudo-ginseng extract product in the experiment of the liver X0D activity influence of hyperuricemia rat model, Wu
The nothing impact on XOD activity of the centipede Radix Notoginseng extract.
Originally test result indicate that centipede pseudo-ginseng extract product high, medium and low dosage group all can significant impact high hematuria acid disease
The serum uric acid level of rat, and the effect of the blood uric acid of its dosage group high, middle high hematuria acid disease rat of reduction is more significantly,
But, under this experiment condition, this has been tested and has indicated this natural Chinese medicine extract of centipede pseudo-ginseng extract product,
Acting on the rat through chemical inducer Oteracil Potassium salt treatment modeling, can induce and produce potential reduction urine
The pharmacological action of blood uric acid, and the mechanism of action of centipede pseudo-ginseng extract product reduction Uric Acid Content is not by suppression
The approach of X0D activity realizes.The mechanism of action of centipede pseudo-ginseng extract product is the most unclear at present, thus it is speculated that be probably logical
Cross the effect promoting that blood uric acid metabolism reaches to drop blood uric acid.
5 conclusions
Centipede pseudo-ginseng extract product has reduction serum uric acid level effect to hyperuricemia rat, and not by suppression
Expressing of xanthine oxidase plays therapeutic effect.
Two, the centipede pseudo-ginseng extract product impact on mouse hyperuricemia
1 experiment material
1.1 animal
1.1.1 the centipede pseudo-ginseng extract product impact on hyperuricemia mice uric acid
Healthy SPF level Kunming mouse, male, body weight (24 ± 2) g, effluent north Experimental Animal Center provides, and closes
Lattice card number: SCXK (Ji) 2008-1-003.In whole experimentation, in addition to experiment modeling particular/special requirement, animal is equal
Freely drink water and subsist, raising room temperature 22 ± 2 DEG C.
1.2.2 the centipede pseudo-ginseng extract product impact on the acid of normal mouse retention
Healthy SPF level Kunming mouse, male, body weight (30 ± 2) g, effluent south Experimental Animal Center provides, and closes
Lattice card number: SCXK (Henan) 2010-0002.In whole experimentation, in addition to experiment modeling particular/special requirement, animal is equal
Freely drink water and subsist, raising room temperature 22 ± 2 DEG C.
1.2 medicines and reagent
Centipede pseudo-ginseng extract product (total saponin content about 60%): prepared by conventional decocting method, take Scolopendra pseudo-ginseng, add 2～
The soak by water 3 of 8 times of quality～5 times, each 1～4h, filter, merging filtrate, filtrate is condensed into 60 DEG C the closeest
Degree 1.04～～the liquid of 1.1, let cool, add ethanol and make containing alcohol capacity be 40～80%, stir evenly, stand 12h, filter,
Reclaim ethanol, evaporate into without alcohol taste, obtain extractum, be dissolved in water, clarification, upper nonpolar or low pole macroporous absorption tree
Fat post, washes with water, discards, then with 50～80% ethanol elution, collects eluent, reclaim ethanol, concentrate, in
It is dried 12h under vacuum, pulverizes, cross 60 mesh sieves, obtain centipede pseudo-ginseng extract product.Described centipede pseudo-ginseng extract product is palm fibre
Yellow powder, is made into desired concn with distilled water.
Sodium carboxymethyl cellulose (CMC-Na): analytical pure, is provided by Chinese Medicine Solution on Chemical Reagents in Shanghai station.
Allopurinol (Allopurinol, AP): provided by Sigma-Aldrich company, lot number: 11M1681V, uses
0.5%CMC-Na is made into debita spissitudo.
Oxonic acid potassium salt (Oxonic acid potassium salt, purity 97%): provided by Sigma-Aldrich company,
Lot number: STBC1486V, is made into debita spissitudo with 0.5%CMC-Na.
Uric acid (Uric acid, UA) test kit (urinary acidification): purchased from Shanghai Foxing Changzheng medical science Co., Ltd.
1.3 experimental apparatus
CJ-2F Medical purification workbench: Suzhou City Feng Laboratory Animal Equipment Co., Ltd.
TGL-16gR high speed centrifuge: Anting Scientific Instrument Factory, Shanghai.
Olympus AU400 automatic clinical chemistry analyzer.
2 experimental techniques
The impact on hyperuricemia mice uric acid of 2.1 centipede pseudo-ginseng extract product
2.1.1 packet and administration
Male mice 60, by body weight random packet: normal group, model group, centipede pseudo-ginseng extract product are high, medium and low
Dosage group (respectively 416mg/kg, 208mg/kg and 104mg/kg), positive controls (allopurinol 10mg/kg),
Totally 6 groups, often group 10.Gastric infusion, every day 1 time, continuous 10 days.Mouse Weight one is weighed respectively before administration
Secondary, administration volume is pressed 20mL/kg, normal group and model group and is given equal-volume distilled water.
2.1.2 the mensuration of Mouse Blood uric acid level
After last is administered 1h, each group mouse peritoneal injection oxonic acid potassium salt 300mg/kg causes hyperuricemia, normally
Group lumbar injection equal-volume 0.5%CMC-Na.After injection, 1h respectively organizes and all plucks eyeball and take blood (before taking blood, 12h fasting be can't help
Water), left at room temperature 1h, it is centrifuged 10min at 2000r/min, takes serum and be placed in 4 DEG C of preservations.By uric acid reagent box
Description operates, and Olympus AU400 automatic clinical chemistry analyzer measures serum uric acid level.
2.1.3 statistical procedures
Result is with mean ± standard deviationRepresent, between two groups, compare t inspection, P < 0.05, represent difference tool
Statistically significant.
The impact on the acid of normal mouse retention of 2.2 centipede pseudo-ginseng extract product
2.2.1 packet and administration
Male mice 50, by body weight random packet: normal group, centipede pseudo-ginseng extract product high, medium and low dosage group (point
Wei 416mg/kg, 208mg/kg, 104mg/kg), positive controls (allopurinol 10mg/kg), totally 5 groups,
Often group 10.Gastric infusion, every day 1 time, continuous 10 days.Weigh Mouse Weight respectively once before administration, be administered
Volume presses 20mL/kg, and normal group gives equal-volume distilled water.
2.2.2 the mensuration of Mouse Blood uric acid level
Last is administered after 2h, and each treated animal is plucked eyeball and taken blood (before taking blood, water is can't help in 12h fasting), left at room temperature 1h,
It is centrifuged 10min at 2000r/min, takes serum and be placed in 4 DEG C of preservations.Operate by uric acid reagent box description, measure hematuria
Sour water is put down.
2.2.3 statistical procedures
Same 2.1.3.
3 experimental results
The impact on hyperuricemia mice serum uric acid level of 3.1 centipede pseudo-ginseng extract product
The results are shown in Table 3.Under this experiment condition, comparing with normal group, model group Mouse Blood uric acid level significantly increases
(P < 0.01), shows modeling success.Comparing with model group group, in centipede pseudo-ginseng extract product, low dose group can different journeys
Degree ground reduces the uric acid level of metabolic arthritis mice, has significant difference (P < 0.05), and wherein, middle dosage group effect is best；
Centipede pseudo-ginseng extract product high dose group is invalid；Allopurinol group can reduce metabolic arthritis mice serum uric acid level, has
Significant difference (P < 0.01).Compare centipede pseudo-ginseng extract product uric acid resisting action intensity with allopurinol group and be weaker than other purine
Alcohol group.
The impact on hyperuricemia Mouse Blood uric acid of table 3 centipede pseudo-ginseng extract product
| Group | Dosage (mg/kg) | Number of animals | Serum uric acid level (mmol/L) |
| Normal group | - | 9 | 173.04±43.95** |
| Model group | - | 9 | 267.06±57.52 |
| Centipede pseudo-ginseng extract product high dose group | 416 | 10 | 274.19±76.19 |
| Dosage group in centipede pseudo-ginseng extract product | 208 | 9 | 197.72±56.56* |
| Centipede pseudo-ginseng extract product low dose group | 104 | 8 | 205.74±33.32* |
| Allopurinol group | 10 | 9 | 47.58±14.17** |
Note: compare with model group,*P < 0.05,**P<0.01。
The impact on Normal Mouse Serum uric acid level of 3.2 centipede pseudo-ginseng extract product
The results are shown in Table 4.Under this experiment condition, comparing with normal group, Normal Mouse Serum is urinated by centipede pseudo-ginseng extract product
Sour water is flat not to make significant difference；Allopurinol group can reduce Normal Mouse Serum uric acid level, has significant difference
(P<0.01)。
The impact on normal Mouse Blood uric acid of table 4 centipede pseudo-ginseng extract product
| Group | Dosage (mg/kg) | Number of animals | Serum uric acid level (mmol/L) |
| Normal group | - | 10 | 125.12±51.12 |
| Centipede pseudo-ginseng extract product high dose group | 416 | 10 | 125.95±29.55 |
| Dosage group in centipede pseudo-ginseng extract product | 208 | 9 | 130.77±24.40 |
| Centipede pseudo-ginseng extract product low dose group | 104 | 9 | 142.13±32.07 |
| Allopurinol group | 10 | 10 | <10** |
Note: compare with normal group,**P<0.01。
4 discuss
In centipede pseudo-ginseng extract product, low dose group (respectively 208mg/kg and 104mg/kg) high urine can be significantly decreased
Acidemia mice serum uric acid level, and centipede pseudo-ginseng extract product to the serum uric acid level of normal mouse without significance shadow
Ring.
Centipede pseudo-ginseng extract product of the present invention does not has reduction serum uric acid level effect to hyperuricemia rat, and not
It is to play therapeutic effect by expressing of suppression xanthine oxidase.Additionally, centipede pseudo-ginseng extract product of the present invention
Significantly decrease hyperuricemia mice serum uric acid level, and to the serum uric acid level of normal mouse without significance shadow
Ring.
Although illustrating the present invention by way of example, but the skilled addressee will appreciate that and be: without departing from this
On the premise of bright design, carry out any possible change or replacement belongs to protection scope of the present invention.
Claims (3)
1. centipede pseudo-ginseng extract product application in the medicine of preparation prevention or treatment hyperuricemia, described
Prepared by centipede pseudo-ginseng extract product decocting method；
The preparation method of described centipede pseudo-ginseng extract product specifically includes: add 2～the soak by water Scolopendra of 8 times of quality
Pseudo-ginseng 3-5 time, each 1-4h；Then filter, concentrated filtrate, let cool；Adding ethanol makes containing alcohol hold
Amount is 40～80%, stands after stirring evenly；Then filter, reclaim ethanol, evaporate into without alcohol taste, obtain extractum；
Be dissolved in water described extractum, clarification；Upper nonpolar or low pole macroporous adsorptive resins, washes with water,
Again with 50～80% ethanol elution, collect eluent, reclaim ethanol, concentrate, dry, pulverize under vacuum,
Sieve and get final product.
Application the most according to claim 1, wherein, described centipede pseudo-ginseng extract product comprises Scolopendra three
Seven total saponins.
Application the most according to claim 1, wherein, the dosage form of described centipede pseudo-ginseng extract product is mouth
Oral dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410084518.8A CN103877177B (en) | 2014-03-10 | 2014-03-10 | Centipede pseudo-ginseng extract product preparation gout medicine in application and medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410084518.8A CN103877177B (en) | 2014-03-10 | 2014-03-10 | Centipede pseudo-ginseng extract product preparation gout medicine in application and medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103877177A CN103877177A (en) | 2014-06-25 |
| CN103877177B true CN103877177B (en) | 2016-09-07 |
Family
ID=50946513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410084518.8A Expired - Fee Related CN103877177B (en) | 2014-03-10 | 2014-03-10 | Centipede pseudo-ginseng extract product preparation gout medicine in application and medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103877177B (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1895375A (en) * | 2006-01-23 | 2007-01-17 | 广州康和药业有限公司 | Extracts of flaccid anemone and use thereof |
| CN103381205B (en) * | 2013-04-23 | 2015-09-09 | 武汉道一堂医药研究院 | Centipede pseudo-ginseng extract product is at the application prepared in medicine against intestinal adhesion and medicine thereof |
-
2014
- 2014-03-10 CN CN201410084518.8A patent/CN103877177B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103877177A (en) | 2014-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106214845A (en) | A kind of pharmaceutical composition with health care and preparation method thereof | |
| CN102266407B (en) | Traditional Chinese medicinal composition for treating hypertension and preparation method thereof | |
| CN103405487A (en) | Chinese medicine compound effective part with effect of treating arthritis | |
| CN104940479A (en) | TCM composition for treating AD diseases | |
| CN102145089B (en) | Traditional Chinese medicine for treating heart failure | |
| CN102233009B (en) | Chinese medicinal composition for promoting nerve regeneration and preparation method and use thereof | |
| CN105055855B (en) | With Chinese medicine composition for improving sleep, strengthen immunity effect and its preparation method and application | |
| Liu et al. | Optimal compatibility proportional screening of Trichosanthis Pericarpium-Trichosanthis Radix and its anti-Inflammatory components effect on experimental zebrafish and coughing mice | |
| CN103816278B (en) | Composition for reducing blood sugar and application thereof | |
| CN102283910B (en) | Chinese medicinal composition with anti-depression effect and preparation and preparation method thereof | |
| CN104721732B (en) | A kind of herbal composite for treating senile dementia | |
| CN103920000B (en) | It is a kind of to treat Chinese medicine composition of osteoporosis and preparation method thereof | |
| CN103877177B (en) | Centipede pseudo-ginseng extract product preparation gout medicine in application and medicine | |
| CN103417630A (en) | Extract of litsea citrata root and applications thereof | |
| CN101850063A (en) | Medicinal preparation for preventing and treating gout and preparation method | |
| CN102266428B (en) | Anti-ageing Chinese medicinal composition and preparation method and application thereof | |
| CN111588800B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN102293957B (en) | Chinese medicinal granules for treating related skin disease such as blood heat yang floating disease and preparation method thereof | |
| CN1188406C (en) | Cattail pollen extract and preparation process and use thereof | |
| CN101491575B (en) | Traditional Chinese medicine extract for treating atopic dermatitis and granules thereof | |
| CN101293073A (en) | Chinese medicinal composition for treating systematic lupus erythematosus | |
| CN104906194B (en) | A kind of medicinal plaster treating asthma and preparation technology and determination method | |
| CN104887766A (en) | Traditional Chinese medicine compound capsules for treating atherosclerosis and preparation method thereof | |
| CN103263581A (en) | Shuangshen capsule for reducing blood sugar | |
| CN114869956B (en) | Pharmaceutical composition for treating post-stroke dyskinesia, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160907 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |